Novo Nordisk has reported the first mid-stage clinical data with its triple G agonist for diabetes in China, as it starts an ...

The GLP-1 market is huge and growing, and depending on how patients acquire and pay for their therapies, traditional data ...

I think ironically, it's actually forced people to look for direct-to-patient offerings because they're kind of like, I don't ...

Shares in Anavex Life Sciences lost more than a third of their value today after the company abandoned a filing for its ...

It claims the trackers violate privacy clauses in the US Health Insurance Portability and Accountability Act (HIPAA) and ...

The FDA has sent a warning letter to ImmunityBio over "false and misleading" comments made by its executive chairman, biotech ...

Spanish pharma group Grifols is planning to sell a minority stake in its US business, via an initial public offering, to ...

At BIO-Europe Spring 2026 in Lisbon, Portugal, web editor Nicole Raleigh spoke with Dr Olga Nissan, vice president of ...

MSD's glut of pipeline-boosting deals in the build-up to a looming patent cliff has continued with a $6.7 billion bid to ...

Recent developments in the biopharma AI world include a big financing for Verily, plus news from Zealand Pharma, Latent Labs, ...

The group, known as LAPSUS$, maintain that they have stolen around 3GB of compressed AZ data, but somewhat unusually are ...

Karyopharm is hoping to broaden the label for its first-in-class blood cancer therapy Xpovio to include myelofibrosis, even ...